Burjeel Holdings opens Thalassemia & Sickle Cell Center at BMC

The centre offers integrated outpatient services and a dedicated transfusion unit.

Burjeel Holdings has announced the launch of a new Thalassemia & Sickle Cell Center at its flagship quaternary care hospital, Burjeel Medical City (BMC) in Abu Dhabi.

The new centre offers fully integrated outpatient services and includes a dedicated transfusion unit that operates daily.

The facility’s key features include extended transfusion services, MRI-based quantification of iron overload in the heart and liver, and in-house molecular genotyping.

The centre will also work closely with the Center for Research on Rare Blood Disorders at BMC to identify and enrol eligible patients in international clinical trials.